FibroBiologics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
FBLG$0.92-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
Balance Sheets
(in thousands, except shares and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $13,985 | $9,163 |
| Prepaid expenses | 225 | 36 |
| Other current assets | 18 | 16 |
| Total current assets | 14,228 | 9,215 |
| Property and equipment, net | 824 | 797 |
| Operating lease right-of-use asset, net | 1,393 | 1,809 |
| Total assets | $16,445 | $11,821 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $2,697 | $1,444 |
| Parent company payable | — | 141 |
| Operating lease liability, short-term | 401 | 362 |
| Liability instrument | — | 7,236 |
| SEPA put option liability | 460 | — |
| Short-term convertible note payable | 9,168 | — |
| Total current liabilities | 12,726 | 9,183 |
| Operating lease liability, long-term | 984 | 1,385 |
| Total liabilities | 13,710 | 10,568 |
| Stockholders’ equity | ||
| Preferred Stock, $0.00001 par value; 10,000,000 shares and 20,000,000 shares authorized as of December 31, 2024 and 2023, respectively | — | — |
| Preferred Stock, $0.00001 par value; 0 shares and 8,750,000 Series A Preferred shares authorized as of December 31, 2024 and 2023, respectively; 0 shares and 8,750,000 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Preferred Stock, $0.00001 par value; 0 shares and 5,000,000 Series B Preferred shares authorized as of December 31, 2024 and 2023, respectively; 0 shares and 4,171,445 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Preferred Stock, $0.00001 par value; 0 shares and 5,000,000 Series B-1 Preferred shares authorized as of December 31, 2024 and 2023, respectively; 0 shares and 89,781 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Preferred Stock, $0.00001 par value; 2,500 Series C Preferred shares authorized; 2,500 shares and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Non-voting Common Stock, $0.00001 par value; 0 shares and 30,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 0 shares and 28,230,842 shares issued and outstanding as of December 31, 2024, and 2023, respectively | — | 1 |
| Voting Common Stock, $0.00001 par value; 100,000,000 shares authorized; 35,085,718 shares and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Additional paid-in capital | 38,253 | 25,609 |
| Accumulated deficit | (35,518) | (24,357) |
| Total stockholders’ equity | 2,735 | 1,253 |
| Total liabilities and stockholders’ equity | $16,445 | $11,821 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.